Bioretec Oy

Bioretec Oy EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bioretec Oy (BRETEC.HE) as of Nov 5, 2026 is -8.69 M EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -4.05 M EUR — a change of 114.29% (lower).

EBITDA

-8.69 MEUR

YoY

114.29%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bioretec Oy is 2025 -8.69 M EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bioretec Oy was 2024 -4.05 M EUR. It decreases by 114.29% lower compared to the previous year.

The Bioretec Oy EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-1.57 M EUR
Jan 1, 2019
-1.61 M EUR
Jan 1, 2020
-1.79 M EUR
Jan 1, 2021
-2.50 M EUR
Jan 1, 2022
-2.11 M EUR
Jan 1, 2023
-2.83 M EUR
Jan 1, 2024
-4.05 M EUR
Jan 1, 2025
-8.69 M EUR
The Bioretec Oy EBITDA history
YEAREBITDAYoY
-8.69 MEUR+114.29%
-4.05 MEUR+43.08%
-2.83 MEUR+34.14%
-2.11 MEUR-15.41%
-2.50 MEUR+39.74%
-1.79 MEUR+11.23%
-1.61 MEUR+2.57%
-1.57 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioretec Oy Stock analysis

What does Bioretec Oy do? Bioretec Oy develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics, operating as a developer, manufacturer, and commercializer of innovative bioresorbable orthopedic implants and implant materials. The company's Activa product portfolio includes bioabsorbable biopolymer products available in the market for pediatric, trauma, and sports surgery applications. Bioretec Oy has a Germany-based subsidiary, BRI.Tech GmbH, and its products are used globally across various medical specialties. The company generates revenue through the sale of its Activa product portfolio, targeting healthcare providers and medical institutions worldwide. The Activa products are designed for bone and soft tissue injury treatments, serving segments in pediatrics, trauma surgery, and sports medicine. Bioretec Oy's global distribution network enables the commercialization of its implants in international markets. Bioretec Oy's business model focuses on the development, manufacturing, and commercialization of bioresorbable orthopedic solutions. The company's products are marketed under the Activa brand, catering to medical professionals in specialized surgical fields. The Germany-based subsidiary BRI.Tech GmbH supports the company's operations in the European market. Bioretec Oy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioretec Oy stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bioretec Oy is -8.69 M EUR in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Bioretec Oy changed from -4.05 M EUR to -8.69 M EUR, representing a 114.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Bioretec Oy since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Bioretec Oy historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bioretec Oy

All Key Metrics — Bioretec Oy